| Cash flow (USD) | Q3 2026 ended Mar 31, 2026 | Q2 2026 ended Dec 31, 2025 | Q1 2026 ended Sep 30, 2025 | Q4 2025 ended Jun 30, 2025 | Q3 2025 ended Mar 31, 2025 | Q2 2025 ended Dec 31, 2024 | Q1 2025 ended Sep 30, 2024 | Q4 2024 ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | -1.99M | -2.22M | -1.79M | -2.10M | -2.22M | -2.03M | -3.13M | -2.36M |
| Depreciation and amortization | 127.6K | 131.0K | 130.8K | 159.1K | 189.1K | 193.8K | 193.5K | 188.5K |
| Cash from operations | -1.93M | -2.05M | -1.59M | -1.70M | -1.99M | -2.19M | -2.59M | -1.48M |
| Capital expenditure | 0 | 1 | -84.3K | -10.2K | 0 | 0 | -46.8K | -98.2K |
| Free cash flow | -1.93M | -2.05M | -1.68M | -1.71M | -1.99M | -2.19M | -2.64M | -1.58M |
| Cash from investing | 0 | 1 | -84.3K | -10.2K | 0 | 0 | -46.8K | -98.2K |
| Cash from financing | -6.7K | 6.07M | 1.25M | 728.1K | 575.5K | 2.28M | 1.71M | 3.12M |
| Net change in cash | -1.94M | 4.02M | -432.9K | -984.0K | -1.42M | 91.8K | -931.5K | 1.54M |
From Nanoviricides, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.